Coronavirus-2-specific T cells Therapy (George Papanicolaou Hospital)

N/A

Report date: 2023/08/29 16:46:46

Base Information

Drug NameCoronavirus-2-specific T cells Therapy (George Papanicolaou Hospital)

Drug Alias NameCoronavirus-2-specific T cellsCoV-2-STs

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGreece

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGeorge Papanicolaou Hospital

China Registration ClassN/A

Develop Information

Active CompaniesGeorge Papanicolaou Hospital

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A